22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › PRAXIS PRECISION MEDICINES INC. › 2024-2025

PRAXIS PRECISION MEDICINES INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and PRAXIS PRECISION MEDICINES INC.’s Form 8-K, filed June 27, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 189Asset managers, any item
  • 776Fund votes
  • June 26, 2025Meeting date

Results at a glance

Meeting of June 26, 2025: 4 items on PRAXIS PRECISION MEDICINES INC.’s Form 8-K, filed June 27, 2025: 2 approved · 2 passed (calculated).

Dissent

Significant dissent: 1 say-on-pay vote (60.7% support).

Notable dissent: 1 director (17.0% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore PRAXIS PRECISION MEDICINES INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by PRAXIS PRECISION MEDICINES INC.

These tallies are PRAXIS PRECISION MEDICINES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 27, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

PRAXIS PRECISION MEDICINES INC. — official shareholder meeting results, meeting held June 26, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Jeffrey Chodakewitz, M.D. 14,596,188---- 2,998,186778,152 83%Passed (calculated)—
Elect Director: Merit Cudkowicz, M.D. 17,499,300---- 95,074778,152 99.5%Passed (calculated)—
2. Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm 18,358,6367,6306,260 --0 99.9%Approved—
3. Advisory Vote on Executive Compensation 10,671,3206,919,7053,349 --778,152 61%Approved—

Source: PRAXIS PRECISION MEDICINES INC., Form 8-K, filed with the SEC on June 27, 2025 — read the filing on EDGAR.

How asset managers voted at the PRAXIS PRECISION MEDICINES INC. 2024-2025 meeting

189 asset managers disclosed a vote on at least one PRAXIS PRECISION MEDICINES INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Jeffrey Chodakewitz, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%WITHHELD
FOR: 14,596,188WITHHELD: 2,998,186
Details: description as filed, official tally, votes by 52 asset managers

Description as filed by funds: To elect the Class II Directors to serve until the 2028 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Jeffrey Chodakewitz, M.D.

PRAXIS PRECISION MEDICINES INC.’s own tally for this item (“Elect Director: Jeffrey Chodakewitz, M.D.”): 14,596,188 for, 2,998,186 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 3,712,298 for, 477,120 withheld.

FOR
FOR: 3,712,298WITHHOLD: 477,120
Largest asset managers voting on “To elect the Class II Directors to serve until the 2028 Annual Meeting of Stockholders and until their respect” at PRAXIS PRECISION MEDICINES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard1,053,7310 00For
T. Rowe Price905,2050 00For
BlackRock452,7580 00For
Fidelity361,3980 035,869Mixed
State Street276,9070 0353For
JANUS INVESTMENT FUND234,4060 00For
Aberdeen00 0150,691Withhold
Charles Schwab142,9450 00For
FRANKLIN STRATEGIC SERIES00 0113,704Withhold
Northern Trust00 062,824Withhold
Equitable35,4370 018,040Mixed
DRIEHAUS MUTUAL FUNDS44,1100 00For
TIAA43,4600 00For
Brighthouse35,0920 06,252Mixed
QUANTITATIVE MASTER SERIES LLC25,9760 00For
Transamerica20,3110 00For
RBB FUND, INC.19,3930 00For
ALPS ETF Trust00 014,808Withhold
Lincoln Financial12,8000 00For
John Hancock5,8320 06,137Mixed
Direxion Shares ETF Trust00 011,037Withhold
HUSSMAN INVESTMENT TRUST10,5000 00For
Global X00 010,448Withhold
UBS00 010,400Withhold
Brinker Capital Destinations Trust10,2560 00For

Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).

Elect Director: Merit Cudkowicz, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%
FOR: 17,499,300WITHHELD: 95,074
Details: description as filed, official tally, votes by 52 asset managers

Description as filed by funds: To elect the Class II Directors to serve until the 2028 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Merit Cudkowicz, M.D.

PRAXIS PRECISION MEDICINES INC.’s own tally for this item (“Elect Director: Merit Cudkowicz, M.D.”): 17,499,300 for, 95,074 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.5% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 4,150,190 for, 39,228 withheld.

FOR
FOR: 4,150,190WITHHOLD: 39,228
Largest asset managers voting on “To elect the Class II Directors to serve until the 2028 Annual Meeting of Stockholders and until their respect” at PRAXIS PRECISION MEDICINES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard1,053,7310 00For
T. Rowe Price905,2050 00For
BlackRock452,7580 00For
Fidelity361,3980 035,869Mixed
State Street277,2600 00For
JANUS INVESTMENT FUND234,4060 00For
Aberdeen150,6910 00For
Charles Schwab142,9450 00For
FRANKLIN STRATEGIC SERIES113,7040 00For
Northern Trust62,8240 00For
Equitable53,4770 00For
DRIEHAUS MUTUAL FUNDS44,1100 00For
TIAA43,4600 00For
Brighthouse41,3440 00For
QUANTITATIVE MASTER SERIES LLC25,9760 00For
Transamerica20,3110 00For
RBB FUND, INC.19,3930 00For
ALPS ETF Trust14,8080 00For
Lincoln Financial12,8000 00For
John Hancock11,9690 00For
Direxion Shares ETF Trust11,0370 00For
HUSSMAN INVESTMENT TRUST10,5000 00For
Global X10,4480 00For
UBS10,4000 00For
Brinker Capital Destinations Trust10,2560 00For

Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).

Advisory Vote on Executive Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

61% Approved · of votes cast

FOR 61%AGAINST
FOR: 10,671,320AGAINST: 6,919,705

Prior year: 70.8% for (June 5, 2024 meeting) ▼ 10.2 pts

Details: description as filed, official tally, votes by 189 asset managers

Description as filed by funds: To approve, on an advisory (non- binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2025 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.

PRAXIS PRECISION MEDICINES INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 10,671,320 for, 6,919,705 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers, with the votes cast as follows:”
Support: 61% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 53 asset managers voting on “To approve, on an advisory (non- binding) basis, the compensation of the named executive officers as disclosed” at PRAXIS PRECISION MEDICINES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard01,053,731 00Against
T. Rowe Price0905,205 00Against
BlackRock8,223444,535 00Against
Fidelity0397,267 00Against
State Street276,907353 00For
JANUS INVESTMENT FUND234,4060 00For
Aberdeen0150,691 00Against
Charles Schwab0142,945 00Against
FRANKLIN STRATEGIC SERIES0113,704 00Against
Northern Trust062,824 00Against
Equitable053,477 00Against
DRIEHAUS MUTUAL FUNDS44,1100 00For
TIAA043,460 00Against
Brighthouse041,344 00Against
QUANTITATIVE MASTER SERIES LLC025,976 00Against
Transamerica020,311 00Against
RBB FUND, INC.19,3930 00For
ALPS ETF Trust014,808 00Against
Lincoln Financial12,8000 00For
John Hancock011,969 00Against
Direxion Shares ETF Trust011,037 00Against
HUSSMAN INVESTMENT TRUST010,500 00Against
Global X010,448 00Against
UBS010,400 00Against
Brinker Capital Destinations Trust10,2560 00For

Fund voting reports, all 53 managers: 611,860 for, 3,576,085 against, 1,670 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 151 asset managers voting on “To approve, on an advisory (non- binding) basis, the compensation of the named executive officers as disclosed” at PRAXIS PRECISION MEDICINES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
ADAGE CAPITAL PARTNERS GP, L.L.C.1,914,5910 00For
Janus Henderson1,431,87834,015 00For
Cormorant Asset Management, LP1,446,3720 00For
Soleus Capital Management, L.P.1,249,7400 00For
T. Rowe Price01,205,913 00Against
PERCEPTIVE ADVISORS LLC1,093,9500 00For
BAKER BROS. ADVISORS LP689,4880 00For
DEERFIELD MANAGEMENT COMPANY, L.P.686,9310 00For
State Street579,2747,372 00For
BlackRock20,732469,796 00Against
GEODE CAPITAL MANAGEMENT, LLC0403,082 00Against
DRIEHAUS CAPITAL MANAGEMENT LLC397,9940 00For
Point720370,817 00Against
CIBC Asset Management Inc0336,392 00Against
FRANKLIN ADVISERS INC0314,103 00Against
VR Adviser, LLC244,8580 00For
Verition Fund Management LLC0199,642 00Against
5AM Venture Management, LLC170,0000 00For
Aberdeen0150,691 00Against
Charles Schwab0142,945 00Against
Northern Trust0128,510 00Against
PFM Health Sciences, LP0126,025 00Against
Alyeska Investment Group, L.P.0107,387 00Against
SILVERARC CAPITAL MANAGEMENT, LLC080,793 00Against
Ally Bridge Group (NY) LLC74,3270 00For

Institutional-manager reports, all 151 managers: 10,339,119 for, 4,779,464 against, 21 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 18,358,636AGAINST: 7,630

Prior year: 99.9% for (June 5, 2024 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

PRAXIS PRECISION MEDICINES INC.’s own tally for this item (“2. Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm”): 18,358,636 for, 7,630 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 4,187,945 for, 1,670 abstained.

FOR
FOR: 4,187,945ABSTAIN: 1,670
Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FO” at PRAXIS PRECISION MEDICINES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard1,053,7310 00For
T. Rowe Price905,2050 00For
BlackRock452,7580 00For
Fidelity397,2670 00For
State Street277,2600 00For
JANUS INVESTMENT FUND234,4060 00For
Aberdeen150,6910 00For
Charles Schwab142,9450 00For
FRANKLIN STRATEGIC SERIES113,7040 00For
Northern Trust62,8240 00For
Equitable53,4770 00For
DRIEHAUS MUTUAL FUNDS44,1100 00For
TIAA43,4600 00For
Brighthouse41,3440 00For
QUANTITATIVE MASTER SERIES LLC25,9760 00For
Transamerica20,3110 00For
RBB FUND, INC.19,3930 00For
ALPS ETF Trust14,8080 00For
Lincoln Financial12,8000 00For
John Hancock11,9690 00For
Direxion Shares ETF Trust11,0370 00For
HUSSMAN INVESTMENT TRUST10,5000 00For
Global X10,4480 00For
UBS10,4000 00For
Brinker Capital Destinations Trust10,2560 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Largest PRAXIS PRECISION MEDICINES INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 20,341,917 shares outstanding at the time of that meeting.

Fund voting reports: top PRAXIS PRECISION MEDICINES INC. shareholders by shares voted on “To approve, on an advisory (non- binding) basis, the compensation of the named executive…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 5.18%
2T. Rowe Price 4.45%
3BlackRock 2.23%
4Fidelity 1.95%
5State Street 1.36%
6JANUS INVESTMENT FUND 1.15%
7Aberdeen 0.74%
8Charles Schwab 0.70%
9FRANKLIN STRATEGIC SERIES 0.56%
10Northern Trust 0.31%
Institutional-manager reports: top PRAXIS PRECISION MEDICINES INC. shareholders by shares voted on “To approve, on an advisory (non- binding) basis, the compensation of the named executive…”, 2024-2025
#Asset manager % of shares outstanding
1ADAGE CAPITAL PARTNERS GP, L.L.C. 9.41%
2Janus Henderson 7.21%
3Cormorant Asset Management, LP 7.11%
4Soleus Capital Management, L.P. 6.14%
5T. Rowe Price 5.93%
6PERCEPTIVE ADVISORS LLC 5.38%
7BAKER BROS. ADVISORS LP 3.39%
8DEERFIELD MANAGEMENT COMPANY, L.P. 3.38%
9State Street 2.88%
10BlackRock 2.41%

Reported PRAXIS PRECISION MEDICINES INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

PRAXIS PRECISION MEDICINES INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
JANUS HENDERSON GROUP PLC2,763,859 13.59%Schedule 13G, filed November 14, 2025
ORBIS INVESTMENT MANAGEMENT LTD2,468,413 12.13%Schedule 13G, filed May 15, 2026
FMR LLC2,156,343 10.60%Schedule 13G, filed May 6, 2026
Perceptive Advisors LLC1,995,986 9.81%Schedule 13G, filed February 17, 2026
Entities affiliated with Perceptive Advisors1,829,735 8.99%Proxy statement (DEF 14A), proxy filed April 30, 2025
Baker Bros. Advisors LP1,753,198 8.62%Schedule 13G, filed May 15, 2026
BlackRock1,416,935 6.97%Form 13F, quarter ended March 31, 2025
Entities affiliated with Point721,248,236 6.14%Proxy statement (DEF 14A), proxy filed April 30, 2025
Morgan Stanley1,213,669 5.97%Form 13F, quarter ended March 31, 2025
Steven A. Cohen1,212,728 5.96%Schedule 13G, filed May 15, 2025

Percentages above are of 20,341,917 shares outstanding, as reported by PRAXIS PRECISION MEDICINES INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At PRAXIS PRECISION MEDICINES INC.'s shareholder meeting held June 26, 2025, in the 2024-2025 proxy season, 189 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 776 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory (non- binding) basis, the compensation of the named executive… — PRAXIS PRECISION MEDICINES INC.'s filing reports the proposal as approved, with 61% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: PRAXIS PRECISION MEDICINES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 27, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PRAXIS PRECISION MEDICINES INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

PRAXIS PRECISION MEDICINES INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “PRAXIS PRECISION MEDICINES (PRAX) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/praxis-precision-medicines-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.